MASH has long been a challenging and progressive liver disease, characterized by fat build-up and inflammation that, if left ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

Medically reviewed by Jay N. Yepuri, MD FibroScan is the brand name for transient elastography, an abdominal ultrasound that ...

Goldman Sachs initiated coverage of 89bio (ETNB) with a Neutral rating and $11 price target 89bio is a late-stage clinical company focused on ...

In October 2024, Sagimet announced that the FDA granted Breakthrough Therapy designation to denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...

The COVID-19 pandemic engulfed the U.S. five years ago this month, leaving not only lingering mental health effects but also long-term physical symptoms. One of those included a condition known as ...

A ≥1-stage improvement in fibrosis was seen in 17.5%, 29.2% and 40.9% of patients (F2-F3) in the placebo, 300 mg and 600 mg arms respectively. The publication also highlights the broad ...

Treatment recommendations I frequent (UpToDate) are supportive of Rezdiffra's utilization in patients with MASH and fibrosis stage F2 or F3 who were unable to lose weight. Q4 and FY24 Rezdiffra ...

Detailed price information for Akero Therapeutics Inc (AKRO-Q) from The Globe and Mail including charting and trades.

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to ...